Critical Medicines Act

–

Page contents Page contents In March 2025, the European Commission proposed the Critical Medicines Act to improve the availability, supply and production of critical medicines within the EU. The CMA also aims to increase access to other medicines of common interest, such as those for rare diseases, and to address the fact that some medicines are not available in certain markets. CMA – key features Strategic Projects for critical medicines or their ingredients can be designated, so that they benefit from easier access to funding and fast-tracked procedures. Public procurement to incentivise the resilience of supply chains of critical medicines or to improve access to other medicines of common interest. Collaborative procurement among different member states will be supported by the Commission at the request of member states, to address availability and access disparities of critical medicines and other medicines of common interest. International partnerships with likeminded countries/regions will be explored, to broaden the supply chain and reduce dependencies on single suppliers. State aid guidelines to assist member states in financially supporting such strategic projects. The CMA has been proposed in the context of the European Health Union , which seeks to ensure that all EU citizens have access to necessary medicines. It complements regulatory measures already proposed, notably the reform of EU pharmaceutical legislation . Related links Press release: Commission welcomes political agreement on Critical Medicines Act Press release: Commission proposes Critical Medicines Act to bolster the supply of critical medicines in the EU Commission Staff Working Document – strengthening the supply of critical medicinal products and medicines of common interest (SWD(2025) 263 final) Critical Medicines Alliance Union list of critical medicines Factsheet – Critical Medicines Act: improving availability & securing supply in the EU Factsheet – EU actions to address medicine shortages & improve security of supply Exploratory study in view of a Critical Medicines Act Medicinal products (European Commission) Latest updates News announcement 21 October 2026 Presentation and recording - EUHPP Live Webinar on Biosimilar policies in practice: key findings from the AUGMENT study visits (19 October 2026) 1 min read News announcement 6 October 2026 Registration - EUHPP Live Webinar on Biosimilar Policies in Practice: Key Findings from the AUGMENT Study Visits (19 October 2026, 9.00-10.00 CEST) 1 min read News announcement 22 September 2026 Agenda - 104th meeting of the Pharmaceutical Committee (6 October 2026) 1 min read News announcement 10 July 2026 Questions and answers (version 22) - Safety features for medicinal products for human use 1 min read See all Documents Events Consultations Publications Videos Eurobarometers